腸チフスVi多糖体ワクチンの世界市場レポート 2024

腸チフスVi多糖体ワクチンの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には17.9%の年間複合成長率（CAGR）で112億8,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、予防接種プログラムの拡大、世界の保健政策への注目の高まり、疫学調査の改善、旅行医療の需要の増加、さまざまな環境的および社会的影響によるものと考えられます。この期間に予想される主な動向には、研究開発（R&D）への投資の増加、規制の裏付けの強化、疫学研究の強化、公衆衛生問題に関する国民の意識の高まりなどが含まれます。

腸チフスの蔓延により、腸チフスVi多糖体ワクチン市場の拡大が予想されます。腸チフスは、腸チフス菌によって引き起こされる潜在的に致死的な感染症であり、通常、汚染された食べ物や飲み物を介して感染します。 腸チフスVi多糖体ワクチンは予防策として機能し、Salmonella enterica血清型チフス菌（S. Typhi）によって引き起こされる腸チフスに対する予防接種を2歳以上の個人に行います。 2021年3月、疾病管理予防センター（CDC）は、米国におけるチフス菌感染症の推定年間症例数が5,700人で、そのうち約620人が入院を必要としていると報告しました。世界中で腸チフスは毎年1,100万人から2,100万人が感染し、20万人が死亡しています。したがって、腸チフスの有病率の上昇は、腸チフスVi多糖体ワクチン市場の成長を促進する極めて重要な要因です。

予防接種キャンペーンの成長により、腸チフスVi多糖体ワクチン市場の拡大がさらに促進される見込みです。国レベルまたは地方レベルで実施される戦略的取り組みである予防接種キャンペーンは、多くの人々にワクチンを迅速に届けるために重要な役割を果たします。特に、2022年4月にネパールの定期予防接種プログラムに腸チフス結合型ワクチン（TCV）がイントロダクションは、腸チフスと戦うための協調的な取り組みを実証しています。この3週間のキャンペーンは、Gavi、ワクチンアライアンス、世界保健機関、ユニセフ、その他のパートナーの支援を受けて、生後15か月から15歳までのすべての子供にワクチンを接種することを目的としています。学校を含む50,000以上のワクチン接種施設を擁するこのキャンペーンは、腸チフスに対する広範な予防を達成し、ワクチンイントロダクションの効果を高め、抗菌薬耐性の脅威に対処することを目指しています。予防接種キャンペーンへの注目の高まりが、腸チフスVi多糖体ワクチン市場の成長を推進する主な原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の腸チフスVi多糖体ワクチン市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 子供
• 成人
• 世界の腸チフスVi多糖体ワクチン市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口
• 世界の腸チフスVi多糖体ワクチン市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 政府機関
• 民間部門
• その他の用途

第7章 地域および国の分析

• 世界の腸チフスVi多糖体ワクチン市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の腸チフスVi多糖体ワクチン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腸チフスVi多糖体ワクチン市場の競合情勢
• 腸チフスVi多糖体ワクチン市場企業プロファイル
  • Sanofi Pasteur SA
  • GlaxoSmithKline plc
  • Merck &Co. Inc.
  • Pfizer Inc.
  • Johnson &Johnson Private Limited

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

Typhoid Vi Polysaccharide Vaccine Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on typhoid vi polysaccharide vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for typhoid vi polysaccharide vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The typhoid vi polysaccharide vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Child; Adult
• 2) By Route of Administration: Oral; Parenteral
• 3) By Application: Government Institution; Private Sector; Other Applications
• Companies Mentioned: Sanofi Pasteur SA; GlaxoSmithKline PLC; Merck & Co. Inc.; Pfizer Inc.; Johnson & Johnson Private Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

The recommendation for active immunization against typhoid fever caused by Salmonella typhi extends to individuals aged two and above through the Typhoid Vi polysaccharide vaccine.

The primary variants of this vaccine are tailored for pediatric and adult use. A child denotes an individual from birth to puberty or reaching full physical maturity. The vaccine can be administered orally or through parenteral routes and is accessible across governmental, private, and other institutional healthcare settings.

The typhoid Vi polysaccharide vaccine market research report is one of a series of new reports from The Business Research Company that provides typhoid Vi polysaccharide vaccine market statistics, including typhoid Vi polysaccharide vaccine industry global market size, regional shares, competitors with typhoid Vi polysaccharide vaccine market share, detailed typhoid Vi polysaccharide vaccine market segments, market trends and opportunities, and any further data you may need to thrive in typhoid Vi polysaccharide vaccine industry. This Typhoid Vi polysaccharide vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The typhoid vi polysaccharide vaccine market size has grown rapidly in recent years. It will grow from $4.98 billion in 2023 to $5.84 billion in 2024 at a compound annual growth rate (CAGR) of 17.3%. The growth observed during the historical period can be attributed to several factors, including the prevalence of diseases, global health initiatives, increased vaccination among travelers, government-led immunization campaigns, as well as the effectiveness and safety of vaccines.

The typhoid vi polysaccharide vaccine market size is expected to see rapid growth in the next few years. It will grow to $11.28 billion in 2028 at a compound annual growth rate (CAGR) of 17.9%. The anticipated growth in the forecast period can be credited to the expansion of immunization programs, a heightened focus on global health policies, improved epidemiological surveillance, increased demand for travel medicine, and various environmental and social influences. Key trends expected during this period encompass increased investments in research and development (R&D), strengthened regulatory backing, enhanced epidemiological studies, and heightened public awareness concerning public health issues.

The expansion of the typhoid Vi polysaccharide vaccine market is anticipated, driven by the increasing prevalence of typhoid. Typhoid, a potentially fatal infection caused by Salmonella typhi bacteria, is typically transmitted through contaminated food or drink. The typhoid Vi polysaccharide vaccine serves as a preventive measure, immunizing individuals aged 2 and above against typhoid fever caused by Salmonella enterica serovar Typhi (S. Typhi). In March 2021, the Centers for Disease Control and Prevention (CDC) reported an estimated 5,700 annual cases of Salmonella Typhi infections in the United States, with approximately 620 requiring hospitalization. Globally, typhoid fever is responsible for 11 to 21 million cases and 200,000 fatalities each year. Consequently, the rising prevalence of typhoid is a pivotal factor driving the growth of the typhoid Vi polysaccharide vaccine market.

The growth of immunization campaigns is poised to further fuel the expansion of the typhoid Vi polysaccharide vaccine market. Immunization campaigns, strategic initiatives conducted at national or sub-national levels, play a crucial role in rapidly reaching large populations with vaccines. Notably, the introduction of the Typhoid Conjugate Vaccine (TCV) in Nepal's routine immunization program in April 2022 exemplifies the concerted efforts to combat typhoid. This three-week campaign, supported by Gavi, the Vaccine Alliance, the World Health Organization, UNICEF, and other partners, aims to vaccinate all children aged 15 months to 15 years. With over 50,000 vaccination sites, including schools, the campaign seeks to achieve widespread protection against typhoid, enhance the impact of vaccine introduction, and address the threat of antimicrobial resistance. The increasing focus on immunization campaigns is a key driver propelling the growth of the typhoid Vi polysaccharide vaccine market.

The growth in healthcare sector expenditure is another influential factor driving the expansion of the typhoid Vi polysaccharide vaccine market. Healthcare expenditure, encompassing public and private costs, is a critical determinant of the resources available for vaccine development. In the United States, for instance, the National Health Expenditure Projections for 2018-2027 forecast healthcare expenditure to reach nearly $6.0 trillion by 2027, with an average annual growth rate of 5.5% from 2018. This upward trend in healthcare spending contributes to the development of more typhoid vaccines, consequently increasing demand for the typhoid Vi polysaccharide vaccine. The growth in healthcare sector expenditure is a pivotal factor propelling the expansion of the typhoid Vi polysaccharide vaccine market.

A prominent trend in the typhoid Vi polysaccharide vaccine market is the growing popularity of strategic partnerships, with major companies leveraging collaborations to enhance their positions in this domain. Notably, in July 2022, The International Vaccine Institute, based in South Korea and dedicated to addressing infectious diseases of global health importance, joined forces with Moderna, a leading US-based biopharmaceutical company. This strategic partnership resulted in the development of the world's first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine, showcasing the potential for collaborative efforts to drive innovation in vaccine development.

Major players in the typhoid Vi polysaccharide vaccine market are emphasizing investments to reinforce their standing in the industry. Substantial investments are being directed towards the research, development, and distribution of the typhoid Vi polysaccharide vaccine, underscoring the significance of preventing and controlling typhoid fever. A noteworthy example is the collaboration between SK Bioscience, a South Korea-based biotech company, and Vaxxas, an Australia-based biotechnology company specializing in needle-free vaccination technology. In August 2023, this partnership secured AUD5.4 million ($3.67 million) in funding from Wellcome, a UK-based charity. The funding aims to support the development of a typhoid conjugate vaccine that can be delivered through a needle-free patch, reflecting a commitment to innovative vaccine delivery methods. This collaboration brings together Vaxxas' high-density microarray patch (HD-MAP) platform technology with SK Bioscience's proprietary typhoid vaccine, presenting a potential breakthrough in vaccine delivery mechanisms.

Major companies operating in the typhoid vi polysaccharide vaccine market report are Sanofi Pasteur SA, GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Mylan NV, Serum Institute of India Pvt. Ltd., Biological E. Limited, Panacea Biotec Ltd., Shantha Biotechnics Pvt. Ltd., Cadila Healthcare Ltd., Merck Sharp & Dohme Corp., AstraZeneca Limited, Boryung Pharmaceutical Co., Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2023. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the typhoid vi polysaccharide vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The typhoid Vi polysaccharide vaccine market consists of sales of Vi capsular polysaccharide vaccine, and non-conjugated Vi polysaccharide vaccine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Typhoid Vi Polysaccharide Vaccine Market Characteristics

3. Typhoid Vi Polysaccharide Vaccine Market Trends And Strategies

4. Typhoid Vi Polysaccharide Vaccine Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Typhoid Vi Polysaccharide Vaccine Market Size and Growth

• 5.1. Global Typhoid Vi Polysaccharide Vaccine Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Typhoid Vi Polysaccharide Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Typhoid Vi Polysaccharide Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Typhoid Vi Polysaccharide Vaccine Market Segmentation

• 6.1. Global Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Child
• Adult
• 6.2. Global Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• 6.3. Global Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Government Institution
• Private Sector
• Other Applications

7. Typhoid Vi Polysaccharide Vaccine Market Regional And Country Analysis

• 7.1. Global Typhoid Vi Polysaccharide Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Typhoid Vi Polysaccharide Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market

• 8.1. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Typhoid Vi Polysaccharide Vaccine Market

• 9.1. China Typhoid Vi Polysaccharide Vaccine Market Overview
• 9.2. China Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Typhoid Vi Polysaccharide Vaccine Market

• 10.1. India Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Typhoid Vi Polysaccharide Vaccine Market

• 11.1. Japan Typhoid Vi Polysaccharide Vaccine Market Overview
• 11.2. Japan Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Typhoid Vi Polysaccharide Vaccine Market

• 12.1. Australia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Typhoid Vi Polysaccharide Vaccine Market

• 13.1. Indonesia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Typhoid Vi Polysaccharide Vaccine Market

• 14.1. South Korea Typhoid Vi Polysaccharide Vaccine Market Overview
• 14.2. South Korea Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Typhoid Vi Polysaccharide Vaccine Market

• 15.1. Western Europe Typhoid Vi Polysaccharide Vaccine Market Overview
• 15.2. Western Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Typhoid Vi Polysaccharide Vaccine Market

• 16.1. UK Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Typhoid Vi Polysaccharide Vaccine Market

• 17.1. Germany Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Typhoid Vi Polysaccharide Vaccine Market

• 18.1. France Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Typhoid Vi Polysaccharide Vaccine Market

• 19.1. Italy Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Typhoid Vi Polysaccharide Vaccine Market

• 20.1. Spain Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market

• 21.1. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market Overview
• 21.2. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Typhoid Vi Polysaccharide Vaccine Market

• 22.1. Russia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Typhoid Vi Polysaccharide Vaccine Market

• 23.1. North America Typhoid Vi Polysaccharide Vaccine Market Overview
• 23.2. North America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Typhoid Vi Polysaccharide Vaccine Market

• 24.1. USA Typhoid Vi Polysaccharide Vaccine Market Overview
• 24.2. USA Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Typhoid Vi Polysaccharide Vaccine Market

• 25.1. Canada Typhoid Vi Polysaccharide Vaccine Market Overview
• 25.2. Canada Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Typhoid Vi Polysaccharide Vaccine Market

• 26.1. South America Typhoid Vi Polysaccharide Vaccine Market Overview
• 26.2. South America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Typhoid Vi Polysaccharide Vaccine Market

• 27.1. Brazil Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Typhoid Vi Polysaccharide Vaccine Market

• 28.1. Middle East Typhoid Vi Polysaccharide Vaccine Market Overview
• 28.2. Middle East Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Typhoid Vi Polysaccharide Vaccine Market

• 29.1. Africa Typhoid Vi Polysaccharide Vaccine Market Overview
• 29.2. Africa Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Route Of Admistration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Typhoid Vi Polysaccharide Vaccine Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Typhoid Vi Polysaccharide Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Typhoid Vi Polysaccharide Vaccine Market Competitive Landscape
• 30.2. Typhoid Vi Polysaccharide Vaccine Market Company Profiles
  • 30.2.1. Sanofi Pasteur SA
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. GlaxoSmithKline plc
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Pfizer Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Johnson & Johnson Private Limited
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Typhoid Vi Polysaccharide Vaccine Market Competitive Benchmarking

32. Global Typhoid Vi Polysaccharide Vaccine Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Typhoid Vi Polysaccharide Vaccine Market

34. Typhoid Vi Polysaccharide Vaccine Market Future Outlook and Potential Analysis

• 34.1 Typhoid Vi Polysaccharide Vaccine Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Typhoid Vi Polysaccharide Vaccine Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Typhoid Vi Polysaccharide Vaccine Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer